Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Wednesday, January 14th, 2026, at 3:00 pm PT.A live webcast of the presentation will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay will be available following the live event.About Arcus BiosciencesArcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases. In partnership with industry collaborators, patients and physicians a
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell? [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 [Seeking Alpha]Seeking Alpha
- Arcus Biosciences (NYSE:RCUS) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RCUS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZeMarketBeat
RCUS
Earnings
- 8/6/25 - Beat
RCUS
Sec Filings
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- RCUS's page on the SEC website